

Level 14, Cigna House,  
40 Mercer Street, PO Box 10-254,  
Wellington 6001, New Zealand  
Phone 64 - 4 - 460 4990  
Fax 64 - 4 - 460 4995  
www.pharmac.govt.nz

24 March 2006

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

*By facsimile (1 page)*

**PROPOSED LISTING OF DAPSONE IN THE PHARMACEUTICAL SCHEDULE.**

PHARMAC has entered into a provisional agreement with Link Pharmaceuticals Limited in relation to the listing of Dapsone in the Pharmaceutical Schedule. The details of the listing are as follows:

- Dapsone would be listed in Section B of the Pharmaceutical Schedule from 1 June 2006 at the following prices and subsidies:


Chemical	Presentation	Strength	Brand	Price and Subsidy	Pack Size
Dapsone	Tablet	25 mg	Dapsone	\$95.00	100 tablets
Dapsone	Tablet	100 mg	Dapsone	\$110.00	100 tablets

Prices and subsidies are ex-manufacturer, ex-GST.

- Dapsone will no longer require Exceptional Circumstance approval.

If you wish to make comments regarding this proposal for the PHARMAC Board to consider when making it's decision, please forward them to PHARMAC by **5:00pm, Friday, 7 April 2006**.

Yours sincerely



Stephen Woodruffe  
Therapeutic Group Manager Intern